A Phase 1 interventional study of Dapagliflozin/Metformin and Dapagliflozin in Healthy Volunteers, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-01.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to establish if the same amount of drug is absorbed into the blood after ingesting a combination dapagliflozin/metformin tablet vs. the individual dapagliflozin tablet and individual metformin tablet.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
Drug: Dapagliflozin/Metformin · Drug: Dapagliflozin · Drug: Metformin
Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
Drug: Dapagliflozin/Metformin · Drug: Dapagliflozin · Drug: Metformin
Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
Drug: Dapagliflozin/Metformin · Drug: Dapagliflozin · Drug: Metformin
Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
Drug: Dapagliflozin/Metformin · Drug: Dapagliflozin · Drug: Metformin
Drug pages: Dapagliflozin · Metformin
Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
dapagliflozin tablet 2.5 mg Oral Single dose
metformin IR tablet 850 mg Oral Single dose
Also known as: Glucophage
Drug pages: Dapagliflozin · Metformin
Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
dapagliflozin tablet 5 mg Oral Single dose
metformin IR tablet 1000 mg Oral Single dose
Also known as: Glucophage
bioequivalence will be demonstrated if the 90% confidence interval (CI) for the formulation effect is contained within the interval of 0.8000-1.2500 for AUC(0-t), AUCinf and Cmax with respect to both dapagliflozin and metformin.
Time frame: Immediately prior to administration of the investigational product (IP). After intake of IP PK blood samples will be drawn every 15 minutes for the first hour, every 30 minutes for the second hour and every hour up to 72 h after intake of IP.
To examine the safety and tolerability of the combination of dapagliflozin and metformin.
Time frame: Throughout study (for 4 days in each period and a follow-up visit ~6 days later)
The record gives a start of Jan 2010, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dapagliflozin · Metformin